Assembly Biosciences (NASDAQ:ASMB - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping analysts' consensus estimates of ($1.75) by $0.18, Zacks reports. The firm had revenue of $7.36 million for the quarter, compared to the consensus estimate of $7.05 million. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%.
Assembly Biosciences Stock Performance
ASMB stock traded up $0.11 during mid-day trading on Monday, hitting $11.12. The company had a trading volume of 25,324 shares, compared to its average volume of 24,453. Assembly Biosciences has a 12 month low of $10.27 and a 12 month high of $19.93. The stock's fifty day moving average price is $12.91 and its two-hundred day moving average price is $15.13. The firm has a market cap of $70.68 million, a PE ratio of -1.65 and a beta of 0.62.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "neutral" rating on shares of Assembly Biosciences in a research report on Monday.
Read Our Latest Stock Analysis on Assembly Biosciences
Insider Activity
In other news, Director Michael Houghton purchased 3,202 shares of the company's stock in a transaction dated Monday, December 30th. The shares were purchased at an average price of $15.61 per share, with a total value of $49,983.22. Following the transaction, the director now directly owns 3,202 shares of the company's stock, valued at approximately $49,983.22. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.10% of the company's stock.
About Assembly Biosciences
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Featured Stories
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
